Bristol-Myers Squibb Co (LIM:BMY) Tariff Resilience Score: 6/10 (As of Jul. 06, 2026)


LIM:BMY Bristol-Myers Squibb Co LIM:BMY
57 GF Score
Price $56.98
GF Value $48.23
Valuation Modestly Overvalued
! 6 Warning Signs
View Full Analysis

What is Bristol-Myers Squibb Co Tariff Resilience Score?

Bristol-Myers Squibb Co LIM:BMY 57 Tariff Resilience Score is 6 as of Jul. 06, 2026. GuruFocus rates LIM:BMY with a GF Score™ of 57/100 and a GF Value™ of $48.23 (Modestly Overvalued). The stock has 6 warning signs investors should review. Among 1,030 Drug Manufacturers companies, Bristol-Myers Squibb Co ranks better than 91.07% on this metric.

Bristol-Myers Squibb Co has the Tariff Resilience Score of 6, which implies that the company might have Average Resilient.

Bristol-Myers Squibb Co has Pharmaceuticals face moderate tariff risks. Global operations with diverse supply chain. Historical resilience due to essential nature of products and ability to adjust pricing. Some exposure to raw material tariffs.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Bristol-Myers Squibb Co might have Average Resilient.

Bristol-Myers Squibb Co  (LIM:BMY) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Bristol-Myers Squibb Co Tariff Resilience Score Related Terms

LIM:BMY vs PFE, GILD, AMGN: Tariff Resilience Score Comparison

For the Drug Manufacturers - General subindustry, Bristol-Myers Squibb Co's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Bristol-Myers Squibb Co Tariff Resilience Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Bristol-Myers Squibb Co's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Bristol-Myers Squibb Co's Tariff Resilience Score falls into.


LIM:BMY
57GF Score
Bristol-Myers Squibb Co LIM:BMY
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 6 mean?
Bristol-Myers Squibb Co (LIM:BMY) has a Tariff Resilience Score of 6 as of Jul. 06, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Bristol-Myers Squibb Co ranks #92 out of 1030 companies in the Drug Manufacturers industry, placing it in the top 8.9%.
Is Bristol-Myers Squibb Co's Tariff Resilience Score too high?
Bristol-Myers Squibb Co's current Tariff Resilience Score is 6. Based on the distribution chart, Bristol-Myers Squibb Co ranks #92 out of 1030 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Bristol-Myers Squibb Co has a GF Score™ of 57/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Bristol-Myers Squibb Co's Tariff Resilience Score compare to PFE and GILD?
According to the Drug Manufacturers industry distribution chart, Bristol-Myers Squibb Co ranks #92 out of 1030 companies for Tariff Resilience Score. This places Bristol-Myers Squibb Co in the top 9% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Drug Manufacturers company?
A good Tariff Resilience Score depends on the Drug Manufacturers industry context. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. Bristol-Myers Squibb Co's current Tariff Resilience Score is 6. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bristol-Myers Squibb Co stock overvalued right now?
Based on GuruFocus' analysis, Bristol-Myers Squibb Co (LIM:BMY) is currently considered Modestly Overvalued. The stock's GF Value™ is $48.23, compared to a current price of $56.98 — trading 18.1% above its estimated fair value. The current Tariff Resilience Score is 6. Bristol-Myers Squibb Co's overall GF Score™ is 57/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Bristol-Myers Squibb Co (LIM:BMY), the current Tariff Resilience Score is 6 as of Jul. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Bristol-Myers Squibb Co (LIM:BMY) Overvalued in 2026?

Based on GuruFocus' analysis, Bristol-Myers Squibb Co stock appears to be overvalued. The current stock price of $56.98 is trading 18.1% above its estimated GF Value™ of $48.23. GuruFocus considers Bristol-Myers Squibb Co to be Modestly Overvalued.

Key valuation signals for LIM:BMY:

  • Tariff Resilience Score: 6
  • GF Value™: $48.23 vs. price of $56.98 (18.1% above fair value)
  • GF Score™: 57/100 with 6 warning signs

No single metric tells the full story. See the LIM:BMY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Bristol-Myers Squibb Co Business Description

Address Route 206 and Province Line Road, Princeton, New Jersey, NJ, USA, 08543
Bristol Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
57GF Score

Get the complete analysis for LIM:BMY

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$56.98
Price
$48.23
GF Value